Battle for Weight-Loss Dominance: Novo Nordisk Charts Next Phase as Eli Lilly Gains Ground in GLP-1 Race
Novo Nordisk is navigating a pivotal phase in the weight-loss market as competitor Eli Lilly gains market share with Zepbound. Explore how both pharmaceutical leaders…